Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.
Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results from a rival Novo Nordisk (NVO) drug.
Sanders says generic drugmakers could sell Novo Nordisk Ozempic for less than $100
Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...
Novo Says Ozempic ‘Very Likely’ Target for Next US Price Cut
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a ...
NJBIZ1d
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
NationofChange2d
Bernie Sanders calls out Big Pharma over exorbitant drug prices: Novo Nordisk’s $900+ charge for a drug that could be sold for $100
As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Cheap Ozempic is coming: Cost could soon be slashed for millions of Americans, drugmaker confirms — here’s how
Get the skinny on this. Novo Nordisk, the Danish pharmaceutical company that manufactures Ozempic, said that it is “very ...